Annovis Stock Performance

ANVS -  USA Stock  

USD 13.04  0.49  3.62%

The firm shows a Beta (market volatility) of 1.8493, which signifies a somewhat significant risk relative to the market. Let's try to break down what Annovis's beta means in this case. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Annovis Bio will likely underperform. Even though it is essential to pay attention to Annovis Bio historical returns, it is always good to be careful when utilizing equity current trending patterns. Our philosophy towards foreseeing any stock's future performance is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Annovis Bio exposes twenty-eight different technical indicators, which can help you to evaluate its performance. Annovis Bio has an expected return of -1.08%. Please be advised to confirm Annovis Bio treynor ratio, as well as the relationship between the expected short fall and day median price to decide if Annovis Bio performance from the past will be repeated at some point in the near future.

Annovis Stock Performance 

 
Refresh
Annovis Performance
0 of 100
Over the last 90 days Annovis Bio has generated negative risk-adjusted returns adding no value to investors with long positions. Even with fragile performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in February 2022. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more

Annovis Price Channel

Quick Ratio42.35
Fifty Two Week Low9.71
Target High Price70.00
Fifty Two Week High132.00
Target Low Price70.00

Annovis Bio Relative Risk vs. Return Landscape

If you would invest  2,903  in Annovis Bio on October 25, 2021 and sell it today you would lose (1,599)  from holding Annovis Bio or give up 55.08% of portfolio value over 90 days. Annovis Bio is currently does not generate positive expected returns and assumes 5.801% risk (volatility on return distribution) over the 90 days horizon. In different words, 49% of stocks are less volatile than Annovis, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
 Daily Expected Return (%) 
      Risk (%) 
Given the investment horizon of 90 days Annovis Bio is expected to under-perform the market. In addition to that, the company is 6.92 times more volatile than its market benchmark. It trades about -0.19 of its total potential returns per unit of risk. The DOW is currently generating roughly -0.07 per unit of volatility.

Annovis Bio Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Annovis Bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Annovis Bio, and traders can use it to determine the average amount a Annovis Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = -0.1861

Best
Portfolio
Best
Equity
Good Returns
Average Returns
Small Returns
CashSmall
Risk
Average
Risk
High
Risk
Huge
Risk
Negative ReturnsANVS
Estimated Market Risk
 5.8
  actual daily
 
 49 %
of total potential
 
4949
Expected Return
 -1.08
  actual daily
 
 0 %
of total potential
 
00
Risk-Adjusted Return
 -0.19
  actual daily
 
 0 %
of total potential
 
00
Based on monthly moving average Annovis Bio is performing at about 0% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Annovis Bio by adding it to a well-diversified portfolio.

About Annovis Bio Performance

To evaluate Annovis Bio Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Annovis Bio generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Annovis Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Annovis Bio stock market performance in a much more refined way. At Macroaxis, we take it even further. The Macroaxis performance score is an integer between 0 and 100 that represents Annovis's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Return on Average Assets(0.64) (0.69) 
Return on Average Equity(0.53) (0.55) 
Return on Invested Capital 26.30  21.09 
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania. Annovis Bio operates under Biotechnology classification in the United States and is traded on NYSEMKT Exchange. It employs 2 people.

Things to note about Annovis Bio

Checking the ongoing alerts about Annovis Bio for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Annovis Bio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.

Annovis Bio Alerts

Equity Alerts and Improvement Suggestions

Annovis Bio generated a negative expected return over the last 90 days
Annovis Bio has high historical volatility and very poor performance
Annovis Bio has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 366.66 K. Net Loss for the year was (10.28 M) with profit before overhead, payroll, taxes, and interest of 173.72 K.
Annovis Bio currently holds about 47.46 M in cash with (8.13 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.86.
Annovis Bio has a frail financial position based on the latest SEC disclosures
Roughly 31.0% of the company shares are held by company insiders
Latest headline from www.nasdaq.com: Insiders might want to re-evaluate their US658k stock purchase as Annovis Bio, Inc. drops to US117m - Nasdaq
Please continue to Trending Equities. Note that the Annovis Bio information on this page should be used as a complementary analysis to other Annovis Bio's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Complementary Tools for Annovis Stock analysis

When running Annovis Bio price analysis, check to measure Annovis Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Annovis Bio is operating at the current time. Most of Annovis Bio's value examination focuses on studying past and present price action to predict the probability of Annovis Bio's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Annovis Bio's price. Additionally, you may evaluate how the addition of Annovis Bio to your portfolios can decrease your overall portfolio volatility.
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Is Annovis Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Annovis Bio. If investors know Annovis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Annovis Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Annovis Bio is measured differently than its book value, which is the value of Annovis that is recorded on the company's balance sheet. Investors also form their own opinion of Annovis Bio's value that differs from its market value or its book value, called intrinsic value, which is Annovis Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Annovis Bio's market value can be influenced by many factors that don't directly affect Annovis Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Annovis Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine Annovis Bio value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Annovis Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.